Laura Clague - 15 Jun 2022 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director
Signature
/s/ Laura Clague by Nicholas Khadder, Attorney-in-Fact
Issuer symbol
LAB
Transactions as of
15 Jun 2022
Net transactions value
$0
Form type
4
Filing time
17 Jun 2022, 18:04:26 UTC
Previous filing
12 May 2022
Next filing
16 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +30,914 +65% $0.000000 78,415 15 Jun 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Stock Option (Right to Buy) Award $0 +42,571 $0.000000 42,571 15 Jun 2022 Common Stock 42,571 $1.86 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units that vest in full on the earlier to occur of June 15, 2023 and one day prior to the date of the Issuer's next annual meeting of stockholders. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control.
F2 Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above.
F3 The Option becomes exercisable in twelve equal monthly increments beginning on July 15, 2022.